Premark PHARMA

We are focused on the development and commercialisation of topical treatments for inflammatory diseases of the skin, eye, mucosae and mucocutaneous surfaces

Find out more

Our Company

  • Premark Pharma is a privately-owned company, established in Switzerland in April 2018
  • The lead investor is a consortium of US-based ophthalmologists
  • The team includes experts in ophthalmic clinical practice, drug development and strategic marketing

Our Target

  • Blepharitis is a common, chronic inflammatory eye disease for which there is currently no approved treatment
  • Premark Pharma’s primary business objective is to achieve a marketing approval in EU and US for the first prescription treatment for blepharitis

Our Lead Asset

  • PMP2207 is a novel ocular anti-inflammatory
  • In a robustly designed Phase II study, when compared to vehicle, PMP2207 demonstrated a more rapid and sustained improvement in both the signs and symptoms of blepharitis
  • PMP2207 will be advanced into a Phase III programme in the coming months